Bad News: Two Swine Flu Shots Needed for Children

by Dr. Clark Hansen, NMD | Sep 22, 2009

Clinical trials among young children indicate that they will need two swine flu shots in order to develop adequate antibody levels to fend off the flu, according to public-health experts data released on Monday, September, 21, 2009.

The government Advisory Committee on Immunization Practices is recommending that all children ages 6 months through age 9 be given two vaccine shots at 21 days apart.

However, older children between the ages of 10 and 17 appear to have a “robust immune response” after one shot, meaning they only need to get the vaccine once, according to officials with the National Institute of Allergy and Infectious Diseases.

Preliminary results from the small clinical trial has shown that a single dose of swine flu vaccine produces an immune response in 76% of 10- to 17-year-olds 8-10 days after they get their shot.

But antibodies to the swine flu virus were found in only 36% of children ages3 to 9 after the first shot and only 25 percent of infants and toddlers between 6 and 35 months.

That means that infants and toddlers facing their first-ever vaccinations will need 4 shots: 2 for seasonal flu and 2 for the 2009-H1N1 swine flu.

Is the Vaccine Worth the Risk?

That’s a lot of immune and nervous system stress, including high doses of ethyl mercury in Thimeosal, the vaccine’s preservative, within a very short period of time. Is the vaccine worth the risk of serious neruological damage?

So far this year, Arizona has recorded only 1,480 lab-confirmed cases of the Swine flu, which includes 297 cases that led to hospitalization and 22 deaths that included 4 children.

Arizona has designated infants and young children, kids with chronic health infections and pregnant women as the highest priority for receiving the H1N1 vaccine. Next in line will be school-age students and adults who care for newborns or have chronic conditions such as asthma and diabetes.

There are roughly 1 million children in the state of Arizona who fall between 6 months and 9 years of age, according to Will Humble, the interim director of the Arizona Department of Health Services.

The state expects to receive between about 1 million doses of the swine flu vaccine in mid-October, with more to come weekly throughout the remainder of the flu season.

To read Dr. Hansen’s article: Should You Get the Swine Flu Vaccine? click here.

To see Dr. Hansen’s Natural Treatment Alternatives for the Flu, click here.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Click Here to see the full Report of the Research

Bar chart showing distribution of common cancer types with breast cancer most prevalent.

Infographic on disease status and median duration since diagnosis.

Join Our Community

Call to Schedule Your Appointment Today! (480) 991-5092.